Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSCTlite versus standard care for treatment-resistant Crohn's disease
ISRCTN17160440Phase 3Completed
- Sponsor
- Barts Health NHS Trust
- Start
- Apr 2018
- Modality
- Stem Cell Therapies → Cell Therapies
01
Overview
Phase 3, randomised, open-label trial of autologous hematopoietic stem cells in Crohn's disease (2 arms), sponsored by Barts Health NHS Trust. Primary endpoint: Regression of mucosal ulceration. Started Apr 2018; status: completed.
02
Drugs
autologous hematopoietic stem cells
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on ISRCTN17160440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN17160440.